NCT00050778: A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis |
|
|
| Completed | 2 | 334 | US, Europe, RoW | Interferon beta-1a, Rebif®, Alemtuzumab 12 mg, Lemtrada, Alemtuzumab 24 mg | Genzyme, a Sanofi Company, Bayer | Multiple Sclerosis, Relapsing-Remitting | 09/07 | 01/10 | | |